MariMed Inc.
MariMed Inc.
Your view on MRMD
Overview
What the company does, where it operates, and who runs it.
About MariMed Inc.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Jon R. Levine
- Headquarters
- 10 Oceana Way, Norwood, MA, US
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Jon R. Levine
- Headquarters
- 10 Oceana Way, Norwood, MA, US
MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally.
The company offers cannabis genetics produce flowers and concentrates under the Nature's Heritage brand; cannabis-infused products in the form of chewable tablets and powder drink mixes under the brand Kalm Fusion; natural fruit chews under the Betty's Eddies brand; brownies, cookies, and other social sweets under the Bubby's Baked brand; and cannabidiol formulations under the Florance brand.
It also licenses its brands and product formulations, as well as leases cannabis facilities. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
Fair value for MariMed Inc. from FRC's valuation model, read against the market price. MRMD last traded at $0.08; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for MariMed Inc.. Starting points for MariMed Inc.: EPS -$0.04, beta 1.12 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for MariMed Inc.. MariMed Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for MariMed Inc.. Trailing twelve-month EPS for MariMed Inc. stands at -$0.04. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
1-Year Price Target
Low
$2.25
Median
$2.25
High
$2.25
Average target
Analyst Ratings
- Strong Buy0
- Buy1
- Hold0
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrSep 2026 | Next QtrDec 2026 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | -$0.01 | -$0.01 | -$0.04 | -$0.03 |
| Low estimate | -$0.01 | -$0.01 | -$0.04 | -$0.03 |
| High estimate | -$0.01 | -$0.01 | -$0.04 | -$0.03 |
| No. of analysts | 1 | 1 | 1 | 1 |
| Year-ago EPS | -$0.01 | -$0.01 | -$0.04 | — |
| Growth | -33.3% | +14.5% | -7.8% | — |
Revenue Estimate
| Revenue | Current QtrSep 2026 | Next QtrDec 2026 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $41.20M | $39.80M | $162.40M | $167.60M |
| Low estimate | $41.20M | $39.80M | $162.40M | $167.60M |
| High estimate | $41.20M | $39.80M | $162.40M | $167.60M |
| No. of analysts | 1 | 1 | 1 | 1 |
| Year-ago revenue | $40.76M | $41.65M | $159.83M | — |
| Growth | +1.1% | -4.4% | +1.6% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 12, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for MariMed Inc.. MariMed Inc. has reported as a listed company since 2012. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
MariMed Inc. valued side by side against its closest peers. MariMed Inc. is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold MariMed Inc., and how their positions are changing. At a $32.3M market value, institutional positions materially move MariMed Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by MariMed Inc. executives and directors. Shares of MariMed Inc. have traded between $0.07 and $0.23 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
Latest headlines and company announcements for MariMed Inc.. Coverage tracks MariMed Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of MariMed Inc.